BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 10,000 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at $7,593,412.40. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $25.77 on Monday. The company’s fifty day moving average is $24.17 and its two-hundred day moving average is $20.97. BioLife Solutions, Inc. has a 52-week low of $8.92 and a 52-week high of $26.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -18.15 and a beta of 1.87.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.08. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. The business had revenue of $28.33 million during the quarter, compared to analysts’ expectations of $23.80 million. Equities research analysts forecast that BioLife Solutions, Inc. will post -0.36 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on BLFS shares. Northland Securities boosted their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Craig Hallum boosted their price objective on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, TD Cowen raised their target price on BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, July 17th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. According to data from MarketBeat.com, BioLife Solutions presently has a consensus rating of “Moderate Buy” and an average target price of $26.20.

Institutional Trading of BioLife Solutions

Several institutional investors have recently modified their holdings of BLFS. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the second quarter valued at $35,000. Isthmus Partners LLC lifted its holdings in shares of BioLife Solutions by 34.4% during the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 42,265 shares during the period. Register Financial Advisors LLC acquired a new stake in shares of BioLife Solutions during the 1st quarter valued at about $96,000. Canada Pension Plan Investment Board bought a new stake in BioLife Solutions in the second quarter valued at about $122,000. Finally, Arizona State Retirement System acquired a new position in BioLife Solutions in the second quarter worth about $217,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.